4/A: AC Immune CEO Corrects Share Sale Filing

CEO Andrea Pfeifer filed an amendment to correct a previously misreported share transaction involving 10,000 shares.

Summary

• Andrea Pfeifer, CEO of AC Immune SA, filed an amendment to a Form 4 originally submitted on April 16, 2026.
• The amendment corrects a clerical error that previously misidentified a sale of 10,000 shares as a purchase.
• The shares were sold at a weighted average price of $3.1425, with individual transaction prices ranging from $3.05 to $3.19.
• Following the transaction, the reporting person maintains direct beneficial ownership of 3,830,288 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative correction with no material impact on the company's operational or financial health.

Positives

• The filing demonstrates transparency by proactively correcting a reporting error.

Negatives

• The initial filing contained an administrative error regarding the nature of the transaction (purchase vs. sale).

Risks

• Insider selling can sometimes be perceived negatively by the market, though this transaction was executed under a Rule 10b5-1 plan.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this administrative filing.

Industry Context

StockSavvy.ai notes that administrative amendments to SEC filings are common and generally do not reflect changes in company fundamentals or strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is standard practice for corporate executives to avoid potential conflicts of interest regarding insider trading.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine correction of an administrative filing.

Key Dates

Keywords

AC Immune, ACIU, Insider Trading, Form 4, Andrea Pfeifer, Biotech